Talk:Omalizumab
From Wikipedia, the free encyclopedia
 |
This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Mid | This article has been rated as Mid-importance on the importance assessment scale |
Contents |
[edit] says
says it binds to receptors then it says it binds to the IgE itself. i doubt it's both, since they are completely different molecules. Eupedia 22:55, 18 April 2006 (UTC)
- I am not entirely sure how this drug works, but antibodies are perfectly capable of binding two substrates at once. I slapped an {{expert}} tag on the page. If we can't find anyone, I'll read the reserach paper and fix it (might have to bug me and remind me though). Isopropyl 05:43, 2 May 2006 (UTC)
- I believe that it binds to the Fc receptor portion of the IgE antibody molecule. WhatamIdoing (talk) 04:52, 13 January 2008 (UTC)
[edit] Omalizumab
According to the American Academy of Allergy, Asthma and Immunology, the monoclonal antibody is specifically binds to IgE not the Fc episilon R1 receptor. Sorry ;p
[edit] Patent status
Can we give a citation to one or more patents? If so, when will they expire? -- Beland 23:39, 31 July 2007 (UTC)
[edit] External links
External links to patient support groups (especially online chat boards) and blogs are normally not accepted on Wikipedia. Please read the external links policy and the specific rules for medical articles before adding more external links. WhatamIdoing (talk) 04:49, 13 January 2008 (UTC)
In relationship to the increased risk of cancer with omalizumab i presume the author is refering to the figure presented by the manufacturer (Novartis) in their summary of product characteristics (SPC, which can be accessed at emc.medicines.org.uk). The reported figures are; 25 cancers in 5,015 patients treated with Xolair (0.5%) and 5 cancers in 2,854 patients in the control group (0.18%) Novartis also state that the diversity in the type of cancers observed, the relatively short duration of exposure and the clinical features of the individual cases render a causal relationship unlikely. The overall observed incidence rate of malignancy in the Xolair clinical trial programme was comparable to that reported in the general population. As a point of statistical interest, based on the available figures, the number needed to harm (NNH, i.e. the number of patients you would need to treat to observe one additional adverse outcome, in this case cancer) is 309, for those of you interested in statistics the 95%CI is 175 to 1,329 which basically means theres a 95% chance that in the worse case scenario (based on these figures) that for every 175 patients treated one extra will develop a cancer, whilst in the best case scenario (again based on these figures) one extra patient will develop a cancer for every 1,329 patints treated with Xolair. From a critical analysis point of view it is also worth considering that these figures are based on a relativley short trial. Wheather the risk increases with duration of treatment is still unclear. —Preceding unsigned comment added by 77.100.125.149 (talk) 18:51, 18 March 2008 (UTC)
